pituitrin and Lung-Diseases

Topics: Beryllium; Environmental Exposure; Health Education; Humans; Lung Diseases; Norepinephrine; Occupational Diseases; Occupational Exposure; Ozone; Pulmonary Disease, Chronic Obstructive; Respiration, Artificial; Risk Assessment; Sepsis; Sleep Apnea, Obstructive; Vasopressins

Topics: Adrenocorticotropic Hormone; Adult; Alkalosis, Respiratory; Anaphylaxis; Animals; Cardiovascular Diseases; Collagen Diseases; Gastrointestinal Diseases; Gonadotropins; Hematologic Diseases; Hormones, Ectopic; Humans; Hypoxia; In Vitro Techniques; Infant, Newborn; Lung; Lung Diseases; Lung Neoplasms; Microscopy, Electron; Neuromuscular Diseases; Neurotransmitter Agents; Paraneoplastic Endocrine Syndromes; Pulmonary Edema; Pulmonary Embolism; Pulmonary Emphysema; Rats; Respiratory Distress Syndrome, Newborn; Skin Diseases; Syndrome; Vasopressins

Topics: Carcinoma, Small Cell; Central Nervous System Diseases; Endocrine System Diseases; Hormones, Ectopic; Humans; Hyponatremia; Kidney; Lung Diseases; Lung Neoplasms; Osmolar Concentration; Paraneoplastic Endocrine Syndromes; Syndrome; Vasopressins; Water Intoxication; Water-Electrolyte Balance

Topics: Central Nervous System Diseases; Child; Edema; Endocrine System Diseases; Humans; Hyponatremia; Hypopituitarism; Lung Diseases; Male; Middle Aged; Neoplasms; Vasopressins

Topics: Central Nervous System Diseases; Humans; Lung Diseases; Lung Neoplasms; Pituitary Diseases; Pituitary Gland, Posterior; Sodium; Vasopressins

Topics: Acromegaly; Addison Disease; Adult; Central Nervous System Diseases; Diabetes Insipidus; Humans; Hyperthyroidism; Hypothyroidism; Kidney; Lung Diseases; Male; Neoplasms; Pituitary Diseases; Thyroid Diseases; Vasopressins

Topics: Central Nervous System Diseases; Humans; Hypopituitarism; Lung Diseases; Neoplasms; Vasopressins

Topics: Adrenocortical Hyperfunction; Adrenocorticotropic Hormone; Breast Diseases; Endocrine System Diseases; Gynecomastia; Humans; Lung Diseases; Lung Neoplasms; Male; Neoplasms; Syndrome; Vasopressins

To identify predictors of hospital mortality among patients with severe sepsis who were treated with drotrecogin alfa (activated).. Prospective observational cohort study.. A 1400-bed academic medical center.. One hundred two patients treated with drotrecogin alfa (activated) for severe sepsis.. To identify potential risk factors for hospital mortality, the main outcome evaluated, all patients who received drotrecogin alfa (activated) were segregated according to hospital survival. The following characteristics were recorded: age, sex, weight, surgical or nonsurgical, Acute Physiology and Chronic Health Evaluation (APACHE) II score, number of acquired organ-system derangements, mechanical ventilation, use of vasopressors or dobutamine, patient location 24 hours before receiving drotrecogin alfa (activated), source of infection, microbiologically positive culture, and other process-of-care variables. Of the 102 patients, 43 (42.2%) died during their hospitalization. Potential predictors of hospital mortality identified by univariate analysis included greater APACHE II scores, administration of vasopressin or dobutamine, number of acquired organ-system derangements, time to treatment with drotrecogin alfa (activated), intravenous fluid administered before receiving vasopressors or drotrecogin alfa (activated), number of red blood cell transfusions, and administration of inappropriate initial antimicrobial treatment. Multivariate analysis revealed that vasopressin administration (odds ratio [OR] 3.72, 95% confidence interval [CI] 1.95-7.10), number of acquired organ-system derangements (OR 2.30, 95% CI 1.59-3.31), and administration of inappropriate initial antimicrobial treatment (OR 15.5, 95% CI 6.78-35.6) were independently associated with hospital mortality.. Number of acquired organ-system derangements, vasopressin administration, and treatment with an inappropriate initial antimicrobial regimen are independently associated with an increased risk of hospital mortality among patients treated with drotrecogin alfa (activated) for severe sepsis. These findings suggest that other specific medical interventions may increase survival in this patient population.

Topics: Gastrointestinal Diseases; Hospital Mortality; Humans; Inpatients; Intensive Care Units; Lung Diseases; Middle Aged; Prospective Studies; Protein C; Recombinant Proteins; Risk Factors; Sepsis; Severity of Illness Index; Skin Diseases, Bacterial; Soft Tissue Infections; Vasopressins

To investigate the effect of Sanao Tang (SAT) on urine volume and the expression of aquaporin-\ 2 (AQP2) in rats with lung dysfunction induced by passive smoking and lipopolysaccharide.. Totally 45 healthy Specific pathogen Free Wistar Rats were randomized into 3 groups:\ normal control group, model group and SAT group. A rat model of respiratory dysfunction induced by\ exposure to cigarette smoking and lipopolysaccharide (LPS). Lavage of decoction of the Chinese medicine\ was performed for rats in the SAT group. Anires 2005 System was used to analyze the pulmonary\ function. Urine of rats was collected through metabolism cage method. Enzyme-linked immunosorbent\ assay (ELISA) was used to determine content of antidiuretic hormone (ADH), angiotensin Ⅱ (AngⅡ), atrial natriuretic factor (ANP), endothelin 1 (ET-1), nitric oxide (NO) and prostaglandin E2\ (PGE2) in serum, lung and kidney. The expression of AQP2 in rat renal tissue was determined with \ real-time fluorescence quantitative PCR (RT-PCR).. (a) In comparison with the normal control, It was found that enforced vital capacity (FVC),\ 1-second forced expiratory volume/forced vital capacity% (FEV(1)/FVC%), 24 h urine volume content of\ NO and PGE2 were decreased, while AQP2mRNA level and content of ADH, Agn Ⅱ, ANP and ET-1\ were increased in the model group with statistical significance (P < 0.05). (b) In comparison with the\ model group, It was found that FVC, FEV(1), FEV(1)/FVC%, 24 h urine volume, content of PGE2 and NO\ decreased, while AQP2mRNA level, content of ANP, ADH and Ang Ⅱ decreased in the SAT group with\ statistical significance (P < 0.05).. SAT might effectively regulate the urine volume in the modeled rats; ADH, Ang Ⅱ,\ ANP, ET-1, NO and PGE2 might play an important role in the regulation on urine volume by lungs.\ This might be the mechanisms underpinning the function of lung governing water passage in terms\ of the theory of Traditional Chinese Medicine.

Topics: Angiotensin II; Animals; Aquaporin 2; Dinoprostone; Drugs, Chinese Herbal; Endothelin-1; Humans; Lipopolysaccharides; Lung; Lung Diseases; Male; Nicotiana; Rats; Rats, Wistar; Tobacco Smoke Pollution; Urination; Vasopressins

Topics: Extracellular Space; Humans; Hyponatremia; Inappropriate ADH Syndrome; Infant, Newborn; Infant, Very Low Birth Weight; Intensive Care Units, Neonatal; Lung Diseases; Pressoreceptors; Sodium-Potassium-Exchanging ATPase; Vasopressins

Sarcoidosis is a generalized disorder which involves the central nervous system in 5 per cent of patients presenting with the disease. We describe the case of a 22-year-old man who developed central diabetes insipidus with a daily urine production of 14,81 seven weeks after diagnosis of pulmonary sarcoidosis and parotid gland enlargement. Computed tomography showed a contrast enhancement of pituitary gland and stalk, no other intracranial manifestations were demonstrated. Intranasal administration of synthetic antidiuretic hormone (ADH) reduced urine volume to normal levels immediately. After discontinuation of 15 months therapy with corticosteroids and administration of ADH for 29 months spontaneous urine volume didn't exceed 31. The patient has been free of symptoms since discontinuation of therapy.

Topics: Administration, Intranasal; Adult; Diabetes Insipidus; Humans; Lung Diseases; Male; Parotid Diseases; Pituitary Diseases; Sarcoidosis; Vasopressins

Topics: Aged; Antineoplastic Agents; Atrial Natriuretic Factor; Humans; Inappropriate ADH Syndrome; Lung Diseases; Male; Neoplasms; Vasopressins

The role played by prostaglandins in the secretion of ADH and modulation of its action was investigated by testing the effects of prostaglandin synthesis inhibition in patients with SIADH of cerebral or pulmonary origin. Three patients with SIADH of central origin and 3 with SIADH of peripheral origin were subjected to 4 successive water-loading tests. In the first and fourth tests, the patients absorbed water 20 ml/kg bodyweight; in the second test they absorbed alcohol 2.5 ml/kg followed by water 17.5 ml/kg. The third test was preceded by a 3-day inhibition of prostaglandin synthesis with indomethacin 200 mg/day and aspirin 1.5 g/day. In patients with SIADH of peripheral origin the percent water-load excreted after 4 hours was low (less than 35%) with the 4 tests, whereas it reached 80% (p less than 0.001) with the third test (prostaglandin inhibition) in those with SIADH of central origin. Alcohol did not significantly correct the antidiuretic effect in any of the patients in both groups. It is concluded that prostaglandins reduce ADH secretion in central SIADH but do not modify antidiuresis in peripheral SIADH, since ectopic secretion probably does not depend on prostaglandins. The prostaglandin inhibition test therefore seems to be more helpful than the alcohol test to differentiate between central and peripheral SIADH. Further studies, however, are required to confirm these findings.

Topics: Adult; Aged; Aspirin; Brain Diseases; Ethanol; Female; Humans; Inappropriate ADH Syndrome; Indomethacin; Lung Diseases; Male; Middle Aged; Prostaglandin Antagonists; Prostaglandins; Vasopressins; Water

Topics: Aged; Carbamazepine; Demeclocycline; Female; Glucocorticoids; Humans; Inappropriate ADH Syndrome; Lung Diseases; Lung Neoplasms; Male; Phenytoin; Vasopressins

Topics: Chronic Disease; Cyanosis; Humans; Inflammation; Lung Diseases; Male; Middle Aged; Osteoarthropathy, Secondary Hypertrophic; Penicillins; Pneumoconiosis; Smoking; Syndrome; Tetracycline; Tomography, X-Ray; Vasopressins

Topics: Acute Disease; Bronchial Neoplasms; Humans; Lung Diseases; Sensory Receptor Cells; Smoking; Stress, Psychological; Vasopressins

Topics: Blood Pressure; Blood Volume; Cardiac Output; Diuresis; Heart Atria; Heart Conduction System; Hematocrit; Humans; Lung Diseases; Positive-Pressure Respiration; Posture; Pressoreceptors; Pressure; Pulmonary Circulation; Pulmonary Stretch Receptors; Respiration; Sodium; Temperature; Thorax; Vasopressins; Venous Pressure; Water-Electrolyte Balance

Topics: Animals; Bronchial Neoplasms; Hormones, Ectopic; Humans; Lung Diseases; Pneumonia, Staphylococcal; Pneumonia, Viral; Vasopressins

Topics: Aged; Aspergillosis; Female; Humans; Hyponatremia; Lung Diseases; Lung Diseases, Fungal; Male; Middle Aged; Tuberculosis, Pulmonary; Vasopressins

Topics: Humans; Lung Diseases; Middle Aged; Vasopressins

Topics: Brain Diseases; Carcinoma, Bronchogenic; Humans; Lung Diseases; Osmosis; Phenytoin; Urination; Vasopressins; Water-Electrolyte Balance

Topics: Adult; Carcinoma, Bronchogenic; Cryptococcosis; Granuloma; Hormones, Ectopic; Humans; Hypercalcemia; Lung Diseases; Lung Diseases, Fungal; Lymph Nodes; Lymphoma, Non-Hodgkin; Male; Nephrocalcinosis; Radiography, Thoracic; Vasopressins

Topics: Aged; Carcinoma, Bronchogenic; Central Nervous System Diseases; Hormones, Ectopic; Humans; Hyponatremia; Lung Diseases; Male; Middle Aged; Vasopressins

Topics: Central Nervous System Diseases; Endocrine System Diseases; Humans; Hyponatremia; Kidney Tubules; Lung Diseases; Neoplasms; Osmolar Concentration; Vasopressins

Topics: Heart Failure; Humans; Liver Cirrhosis; Lung Diseases; Neoplasms; Nephrosis; Vasopressins; Water-Electrolyte Balance

Topics: Central Nervous System Diseases; Female; Hormones, Ectopic; Humans; Hyponatremia; Lung Diseases; Male; Neoplasms; Vasopressins

Topics: Adult; Arteriosclerosis; Ductus Arteriosus; Ductus Arteriosus, Patent; Familial Primary Pulmonary Hypertension; Humans; Hypertension; Hypertension, Pulmonary; Lung Diseases; Pathology; Pharmacology; Pulmonary Circulation; Rabbits; Research; Vasopressins